Condition
DMD-associated Dilated Cardiomyopathy
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Recruiting1
Unknown1
Not Yet Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT06643442Phase 2Not Yet RecruitingPrimary
Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age
NCT06224660Phase 1RecruitingPrimary
Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscular Dystrophy
NCT06013839Phase 2UnknownPrimary
TXA127 in Non-Ambulant Patients With DMD Cardiomyopathy
Showing all 3 trials